Brivaracetam
- Generic Name
- Brivaracetam
- Brand Names
- Briviact, Briviact (in Italy: Nubriveo)
- Drug Type
- Small Molecule
- Chemical Formula
- C11H20N2O2
- CAS Number
- 357336-20-0
- Unique Ingredient Identifier
- U863JGG2IA
Overview
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
Background
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
Indication
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
Associated Conditions
- Partial-Onset Seizures
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.